Literature DB >> 34817649

Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients.

Zehra Öksüz1, Enver Üçbilek2, Mehmet Sami Serin3, Serkan Yaraş2, Gülhan Örekici Temel4, Orhan Sezgin2.   

Abstract

It has been shown that host factors play an important role in the progression of hepatitis C virus (HCV) infection. Toll-like receptor 2 (TLR2) del and interleukin 28B (IL28B) T alleles can mediate liver inflammation and pathogenesis of hepatocellular carcinoma. In the present study, the possible relationship between the IL28B rs12979860 C/T and TLR2 -196 to -174 del/ins gene variants and different fibrosis stages and host factors in hepatitis C patients was investigated. IL28B and TLR2 polymorphisms in the blood of 50 hepatitis C patients at different stages of fibrosis (24 mild/moderate, 26 advanced) and 24 healthy controls were examined by RT-qPCR. The highest frequency of the TLR2 del (26.9%) and IL28B T (46.2%) alleles was found in hepatitis C patients with the most advanced fibrosis, and the lowest frequency was found in healthy controls. There was a statistically significant difference between hepatitis C patients with advanced fibrosis and healthy controls in terms of the TLR2 del (p = 0.0062) and IL28B T (p = 0.0017) allele frequencies. However, no statistically significant difference was found between the mild/moderate fibrosis and severe fibrosis patient groups in terms of genotype or IL28B and TLR2 polymorphisms (p > 0.05). In addition, there was a significant difference between patients with mild/moderate or advanced fibrosis who carried the TLR2 del allele together with the IL28B CT genotype and healthy controls. The present study emphasizes that the TLR2 and IL28B gene variants cannot be single biomarkers for the determination of fibrosis stage in hepatitis C infection but together can play an important role in predicting severe disease.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34817649     DOI: 10.1007/s00705-021-05302-9

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  23 in total

Review 1.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

2.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

Review 3.  Fibrosis in patients with chronic hepatitis C: detection and significance.

Authors:  T Poynard; V Ratziu; Y Benmanov; V Di Martino; P Bedossa; P Opolon
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

4.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.

Authors:  Carlo Fabris; Edmondo Falleti; Annarosa Cussigh; Davide Bitetto; Elisabetta Fontanini; Sara Bignulin; Sara Cmet; Ezio Fornasiere; Elisa Fumolo; Stefano Fangazio; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Hepatol       Date:  2010-09-19       Impact factor: 25.083

5.  Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation.

Authors:  Angela Dolganiuc; Shilpa Oak; Karen Kodys; Douglas T Golenbock; Robert W Finberg; Evelyn Kurt-Jones; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 6.  Genomics and HCV infection: progression of fibrosis and treatment response.

Authors:  Emilie Estrabaud; Michel Vidaud; Patrick Marcellin; Tarik Asselah
Journal:  J Hepatol       Date:  2012-05-30       Impact factor: 25.083

7.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

8.  Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response.

Authors:  Maria Elisa Mancuso; Silvia Linari; Alessio Aghemo; Dario Bartolozzi; Elena Santagostino; Maria Grazia Rumi; Elisa Fognani; Maria Rosaria Fasulo; Laura Gragnani; Raffaele Bruno; Massimo Morfini; Anna Linda Zignego; Massimo Colombo
Journal:  Thromb Haemost       Date:  2014-02-13       Impact factor: 5.249

9.  In vivo liver expression of TLR2, TLR3 and TLR7 in chronic hepatitis C.

Authors:  G Tarantino; A Di Cristina; R Pipitone; P L Almasio; G Di Vita; A Craxi; S Grimaudo
Journal:  J Biol Regul Homeost Agents       Date:  2013 Jan-Mar       Impact factor: 1.711

10.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.